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Purpose/Objective: The purpose of this study is to evaluate the 
clinical efficacy of High precision IMRT combined with neoadjuvant & 
concurrent MAB for intermediate- & high-risk prostate cancer 
patients. 
Materials and Methods: Between Sep 2000 and Dec 2007, 200 
localized prostate carcinomas (T1-T3, N0M0) were treated with 
neoadjuvant (3-6 months) and concurrent (2months) hormonal 
therapy. Maximum androgen blockade (MAB) was used as hormonal 
therapy. There were 120 high-risk and 80 intermediate-risk group 
patients. Initial PSA level was ranging 4.0-142 ng/ml (median: 
12.5ng/ml) and Gleason score was ranging 5-10 (median: 7). Median 
follow-up duration is 6.04Y (range: 0.7-11.6Y). IMRT was delivered 
with SMLC-IMRT technique using a 2Gy/fraction to a total dose of 
76Gy. GTV was defined as prostate and CTV was defined as GTV+ 
seminal vesicles. PTV margin was 7mm around the CTV except for 
posterior direction. Posterior margin was 5-6mm. We used 3-gold 
markers implanted to the prostate for localization. After radiation 
therapy, no further hormonal therapy was used until PSA failure. The 
PSA failure definition was done according to Phoenix criteria. The 
follow-up interval was every 3months. We evaluate the PSA failure 
free survival rate (PFFS), Overall survival rate (OS) and acute and late 
sequelae by CTCAE (version4.0). 
Results: The PFFS at 5-/ 7-years of intermediate- and high-risk group 
were 96.1%/96.1%, 85.2%/80.5%, respectively. The OS at 5-/7-years of 
each group were 98.7%/97.4%, 95.8%/95.8%, respectively. Although 
the PFFS for high risk group was good, the PFFS for special group 
(>=T3&PSA>=20&GS>=8) was only 65%. The cause of death was another 
cancer (lung, esophagus, stomach). Acute Grade 1/2 genitourinally 
and gastrointesitinal sequelae was observed in 66.0%/6.0%, 2.5%/1.0%, 
respectively. No grade 3 acute sequelae was observed. Late Grade 1 
urogenital and gastrointestinal sequelae were observed in 24.1%, 
9.1%, respectively. Grade3 urethral stricture was observed in 2 
patients. All of them recovered after bougie. No grade 2 or higher 
rectal complication was observed. 
Conclusions: According to our results, short course (3-6months) 
neoadjuvant and concurrent (2 months) MAB with 76Gy irradiation 
with IMRT/IGRT technique would be effective for intermediate& high 
risk prostate cancer patients at 7 years. For the special group 
(>=T3&PSA>=20&GS>=8), another treatment option might be 
necessary.  
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Purpose/Objective: Feasibility and dosimetric comparison of the 
sequential and simultaneous integrated boost IMRT delivery 
techniques on target coverage and normal-tissue sparing. A sequential 
two-phase process,initial and boost irradiation, is the common 
practice for the radiotherapy management of high-risk prostate 
cancer. In this work, we explore the feasibility of using intensity 
modulated radiation therapy (IMRT) simultaneous integrated boost 
(SIB), a single-phase process, to simultaneously deliver high dose to 
the prostate and lower dose to the pelvic nodes, in our setup. 
Materials and Methods: The study included 25 patients of 
intermediate-high risk carcinoma prostate. Patients were immobilized 
with thermoplastic cast in supine position. Target volumes i.e. PTV 
P+SV (Prostate and Seminal vesicles), PTV LN and organs at risk were 
delineated as per the RTOG census guidelines. On Eclipse version 6.5, 
two plans were generated i.e. sequential 3DCRT (4 field box 
technique) followed by seven field IMRT boost & seven field SIB-IMRT. 
Prescribed dose to PTV P+SV was 74 Gy/37#/7.2 wks for sequential 
plan & 74 Gy/27#/5.2 wks for SIB IMRT. Dose to PTV-LN was 50 
Gy/25#/5wks for SEQ IMRT and 54Gy/27#/5.5wks for SIB-IMRT plan. 
Plan comparison was done using dose volume histogram (DVH) in terms 
of target coverage index (CI=target volume covered by prescription 
dose/target volume) and heterogeneity index (HI=D5/D95). For OAR 
maximum and mean doses and volume of OAR receiving different 
doses. 
Results: Results of SEQ-IMRT and SIB-IMRT are summarized in table1. 
SIB-IMRT delivered a higher EQD2 (87 vs 74Gy) to PTV P+SV. Target 
coverage was better with SIB-IMRT both in terms of conformity & 
homogeneity indices. SIB IMRT reduced dose to critical organs at risk 
in terms of mean and max dose. Analysis of DVH parameters (Rectum 
V75, V65, V50, Bladder V75, V65 and Bowel V45) revealed better 
sparing of OARs with SIB-IMRT. 
 
 SIB-IMRT SEQ-IMRT  PTV P+SV Max.(cGy)  8139.40±60.00 8204.25±122.65 
PTV P+SV Mean (cGy) 7771.42±17.88 7609.95±78.35 
PTV P+SV CI 0.9843±0.0127 0.9085±0.05 
PTV P+SV HI 1.0555±0.0008 1.0743±0.0011 
PTV LN Max. (cGy) 7921.87±30.3 7425.37±60.93 
PTV LN Mean(cGy) 5864.47±71.4 5901.97±38.53 
PTV LN CI 0.98261±0.0172 0.99195±0.0061 
PTV LN HI 1.4432±0.0272 1.1261±0.204 
BLADDER Max. (cGy) 7721.97±93.5 7903.87±40.63 
BLADDER Mean(cGy) 5368.5±299.6 6409.7±551.5 
RECTUM Max. (cGy) 7640.7±95.7 7804.15±59.05 
RECTUM Mean(cGy) 5599.25±204.55 6473.00±59.05 
BOWEL Max. (cGy) 5951.45±369.45 5699.47±183.13 
BOWEL Mean(cGy) 2421.45±215.65 2827.42±133.78 
Bladder V75 5.15±5.27 23.99±18.69 
Bladder V65 28.50±6.32 60.31±16.25 
Rectum V75 5.39±13.36 17.47±3.85 
Rectum V65 31.39±13.05 53.85±30.6 
Rectum V50 65.01±14.36 89.36±3.3 
Bowel V45 13.86±4.68 24.4±11.54 
 
Conclusions: Delivery of SIB IMRT was safe and feasible with regard to 
target coverage. SIB-IMRT was superior to sequential IMRT in 
delivering reduced doses to adjoining organs at risk. A further study in 
large volume exploring the role of SIB IMRT with its potential 
dosimetric and radiobiological advantages in carcinoma prostate is 
warranted in our setup. 
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Purpose/Objective: The diagnosis of prostate cancer (PCa) may cause 
psychological distress. The Memorial Anxiety Scale for Prostate Cancer 
(MAX-PC) (Roth A., 2006) is a self-report questionnaire that was 
developed to assess PCa-related anxiety. MAX-PC has proven to be a 
valid and reliable tool which can be translated and adapted for use in 
non-English speaking populations. The aim of this study was to present 
the procedures for cultural adaptation for the Italian population 
together with the preliminary results for psychometric properties. 
Materials and Methods: The study sample was composed of patients 
(pts) diagnosed with PCa who either were on Active Surveillance (AS) 
or underwent radical radiotherapy (RT). Pts filled out MAX-PC before 
undergoing RT or entering the AS protocol. The questionnaire consists 
of 18 items divided into 3 subscales measuring general PCa anxiety, 
anxiety related to prostate specific antigen (PSA) levels, and fear of 
recurrence. The original English version was translated in Italian by 
two independent researchers; the back translation into English was 
performed by two native English-speaking translators. Back 
translations were discussed and re-translated into Italian to obtain a 
final version. Psychometric analyses were performed to obtain 
reliability indexes. Specifically, a) descriptive analyses to detect 
floor/ceiling effect, b) Cronbach's alpha coefficients (α) to estimate 
the internal consistency of the total MAX-PC and the three subscales, 
c) item to total correlation analyses to assess subscales internal 
consistency.  
Results: One hundred and thirty pts (118 AS – low risk, localized PCa; 
12 RT – low to intermediate risk) filled in MAX-PC. Table 1 reports 
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descriptive scores and distribution. No floor/ceiling effect (defined as 
more than 15% of respondents having respectively the lowest/highest 
score) was found except for the 'PSA anxiety' subscale (floor effect, 
72% of respondents). The Cronbach's α coefficients were high (α ≥ 0.70 
good internal consistency) for total score (α = 0.80), 'PCa anxiety' (α = 
0.87) and 'fear of recurrence' (α = 0.77) subscales. Internal consistency 
was lower for 'PSA anxiety' subscale (α = 0.62). The means of item to 
total correlation coefficients were: 0.63 (range 0.45-0.76) for 'PCa 
anxiety', 0.36 (range 0.2-0.46) for 'PSA anxiety' and 0.68 (range 0.65-
0.75) for 'fear of recurrence' (scores below 0.75 suggest deleting the 
item).  
 
  
Conclusions: The 'PCa anxiety' and the 'fear of recurrence' subscales 
showed strong internal consistency and reliability. The reliability of 
'PSA anxiety' subscale was rather weak, as observed in the original 
version of the MAX-PC. Recruitment of RT pts is ongoing. Further 
analyses will include reliability of the questionnaire over time (test 
re-test correlations), factor analyses and test validation to 
discriminate PCa specific related anxiety in an Italian population.  
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Purpose/Objective: We aimed to assess the dosimetric impact of 
advanced delivery RT techniques, including volumetric modulated arc 
therapy (VMAT), intensity modulated RT (IMRT), and intensity 
modulated proton beam RT (IMPT) in high-risk prostate cancer 
patients with sentinel nodes (SN) in the pararectal region. 
Materials and Methods: Plans for VMAT, IMRT and IMPT were 
optimized for 6 of such patients. The prescribed dose was 50.4 Gy to 
the prostate, seminal vesicles, and the pelvic lymph nodes including 
the pararectal SN (PTV2). This was followed by a boost dose of 28 Gy 
to the prostate and seminal vesicles (PTV1). IMRT and IMPT were 
delivered with 7 and 3 beams respectively and VMAT with 2 arcs. Plans 
aimed to cover at least 95% of the planning target volume with 95% of 
the prescribed dose. Results were assessed by comparing Dose-Volume 
Histograms and NTCP between the three treatment modalities. 
Results: Target coverage (PTV1 and PTV2) was improved with IMPT 
when compared to VMAT and IMRT, while coverage of the SN was 
improved with VMAT (D1Gy 67.91±7.5) when compared with IMRT 
(D1Gy 70.08±5.0). The percentages of rectal, bladder, bowel, and 
femoral head volumes were significantly decreased with IMPT when 
compared to VMAT and IMRT. The comparison between VMAT (D1Gy 
50.70±4.1 and D50Gy 33.52±2.5) and IMRT (D1Gy 51.89±3.4 and D50Gy 
36.55±2.2) showed a significant improvement only for the left femoral 
head irradiation, likely due to the IMRT fields spatial distribution. The 
NTCP evaluation using the relative seriality model showed a 
significant improvement for bladder (contracture and volume loss) and 
rectum (bleeding) ≥ grade-3 late toxicity with IMPT (mean±SD, 0.0±0.0 
and 0.4±0.0) when compared with IMRT (mean±SD, 1.4±1.1 and 
4.6±3.3), respectively.  
Conclusions: When compared to 7 beam IMRT, VMAT treatment plans 
showed an improved tumor coverage of the pararectal SN and may be 
considered an optimal solution with X-ray beams. IMPT showed further 
sparing potential of the organs at risk and more favorable NTCP scores 
especially for bladder contraction and volume loss as well as for rectal 
bleeding.  
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Purpose/Objective: The dose distribution has been improved with the 
advance of intensity-modulated radiation therapy (IMRT), the high-
dose treatment has been possible and the adverse event has been 
decreased. According to this evidence, the position as a radical 
treatment option for the prostate cancers in Japan has been 
established. So we expect similar advantages of IMRT, instead of the 
conventional radiation, with an ethical approval of our hospital, a 
total of 20 patients with PSA failure postoperative prostate cancer 
have been treated with IMRT. We herein review and discuss about 
them. 
Materials and Methods: Between April 2003 and Jun 2012, a total of 
20 patients have been treated with IMRT because of PSA failure after 
the radical prostatectomy for prostate cancer. The background of the 
patients is as bellow: the median age was 67years old (52-83), the 
median T stage was T3a (T1c-T3b), the median initial PSA was 
9.9ng/ml (4.15-71), the median Gleason score was 8 (6–10), positive 
surgical margin cases were in 7(35%), the median post operative PSA 
nadir was 0.0475ng/ml (0.003-2.26), and the median PSA before IMRT 
was 0.478ng/ml (0. 001 - 4.15). The body of the patient was fixed 
with Stereotactic Body Frame one hour after urination, and the 
treatment planning CT image was taken and the clinical target volume 
was created according to preoperative CT/MRI images. The part of the 
irradiation was prostate bed only in 4 and prostate bed and lymph 
node in 16. IMRT was performed by 10MV photon from 7 directions. 
The median total irradiation dose was 67.5Gy (66-70). And, the 
median lymph nodes dose was 54Gy (51-57) in a simultaneous boost 
method on target. Combined hormone therapies were 10cases. 
Results: The biochemical non-recurrence rate was 65% after IMRT in 
2-73 months (median; 12.5months) follow-up period. The interval time 
of the biological recurrence after irradiation was 6-73 months 
(median; 18months). Genitourinary toxicities were 6 cases, 
gastrointestinal toxicities were 11 cases and the other was 1 case. 
They were all acute events with Grade 1 in the Common Terminology 
Criteria for Adverse Events v. 4.0 definitions. There is no late adverse 
event. 
Conclusions: IMRT for PSA failure after radical prostatectomy for 
prostate cancer is considered to be effective and safety. For being 
established that it will be as a salvage option for failure cases of 
postoperative prostate cancer, we have to accumulate more cases and 
observe them with long-term follow-up. 
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Purpose/Objective: Surgery is the most common treatment for 
endometrial cancer. It is the reference for precise FIGO staging and 
gives more information on histological prognostic factors (tumor 
extension, grade, myometrium invasion, and involved lymph nodes). 
No one questions the diagnostic value of lymphadenectomy, however 
therapeutic benefit is still an open debate. The aim of this study is to 
evaluate the results of adjuvant radiotherapy in women who suffered 
from endometrial cancer and were treated by hysterectomy with or 
without lymphadenectomy.  
Materials and Methods: Between 2002 and 2009, 97 women with 
histologically proven endometrial cancer were treated in our 
department by adjuvant radiotherapy after hysterectomy with or 
without lymphadenectomy. 
Results: The range of age was 31-80 years (median, 58.1 years). 83 
patients (85.5%) were postmenopausal, 18 patients suffered from 
coexisting comorbidities (18 hypertension, 12 diabetes). Obesity, a 
family history cancer and nulliparity were respectively observed in 
(23, 16, and 20 women). The histopathological diagnosis was obtained 
   
 
